Cronos Group Inc (CRON)

Nov 1, 2026

Cronos Group Inc. (NASDAQ:CRON) has an average 12-month price target of $2.30 from analysts, with a consensus "Buy" rating. The company recently exceeded quarterly expectations, reporting $0.09 EPS on $53.01 million in revenue. Institutional ownership in Cronos Group has increased, though hedge funds and other institutions collectively own 8.71% of the company.

Oct 29, 2026

Cronos Group (NASDAQ:CRON) is attracting attention ahead of its third-quarter 2026 earnings conference call scheduled for November 5th. The company, known for its conservative balance sheet and significant cash position, focuses on branded cannabis products in Canada, Israel, Germany, and other international markets. Investors will be keen to hear about revenue growth, improved margins, and management's plans for capital allocation, including potential acquisitions or shareholder returns.

Oct 29, 2026

Cronos Group (NASDAQ:CRON) is projected to announce its Q3 2026 earnings before the market opens on November 5th, with analysts anticipating earnings of $0.03 per share and revenue of $51.15 million. The company exceeded expectations in the prior quarter, reporting $0.09 EPS against a $0.01 consensus. Despite a "Buy" consensus rating, the average price target of $2.30 is currently below the stock's opening price of $3.35.

Oct 27, 2026

Cronos Group Inc. (CRON) shares rose 2.11% to $3.38 on Tuesday, outperforming the broader market. This rise ended a two-day losing streak for the company's stock, as the NASDAQ Composite and Dow Jones Industrial Average also saw gains.